CGEN, PCIO, ACOR, CRWE, VIVO, - DrStockPick.com Stock Report!
__
CRWE, Crown Equity Holdings, Inc., CRWE.OB
CRWE is a company utilizing today’s technology to advertise, promote and market public companies globally. CRWE’s proprietary network technology allows their publishing department to get their content to millions of readers daily across the world. CRWE publishes financial content to all the major countries and covers all the accredited stock exchanges.
CRWE is currently in the process of expanding its in-house IT infrastructure. Although their current web page load time is better than 75% of other internet websites, when completed, the modifications will raise this load time to better then 90% of other internet websites while increasing website visitor capacity by 400%.
CRWE has also moved to a dedicated in-house advertising server, allowing for faster response and a wider variety of ad space offerings to those interested in advertising on their numerous internet and affiliate internet properties.
** According to CRWE’s CEO, in a Letter to Shareholders:
- CRWE’s financial statements are stronger than they have ever been before.
- CRWE has high-caliber people working throughout its corporation who believe in the company’s vision and strategies. (This year, CRWE has nearly doubled its workforce from 17 to present number of 32. This is after the Company experienced a workforce increase of 225% in 2009.)
- CRWE’s brand is becoming globally recognized. (CRWE’s goal is to have all of CRWE’s clients’ press releases, articles and news content published in every major financial country’s native language.)
- CRWE has an excellent and growing core business.
- CRWE has a strong set of new initiatives, as well as having powerful underlying technologies.
CRWE has recently added Brilliant Innovator, a Pakistan business led by Zeeshan Shabbir with four (4) Middle Eastern correspondents to its CRWENewswire.com team. CRWE is positioned to offer their readers a global perspective on top stories and world affairs from the Middle East, Far East and Europe to its line newswire, as well as having their assistance with developing CRWE’s Arabic language websites.
CRWE is in the process of implementing a forward stock split of its common stock on a one-for-ten basis. An effective date for the split has not been determined but is expected to occur in late July.
This split should benefit CRWE’s shareholders by increasing the liquidity available to investors giving the company the potential to attract more buyers of an institutional nature. Considering the large increase in income CRWE experienced this past year, CRWE is confident their future projected revenue stream will support this financial strategy.
CRWE’s primary goal, is building the Company’s operations so that CRWE may continue to create value for its shareholders.
**************************************************************
PCIO, Marijuana Incorporated
PCIO is a specialty products company that uses the Industrial Raw Materials from CANNABIS SATIVA or the MARIJUANA PLANT.
PCIO’s goal as a corporation is to provide the most beneficial products and services that can enhance the lives of every consumer in all walks of life.
** FINRA has confirmed that it has received sufficient documentation in order to have the new name “Marijuana, Inc.” reflected in the OTC stock market, while the symbol PCIO will remain.
PCIO may have an opportunity to select a new symbol if proposed rules become effective at an unknown date in the future. PCIO expects its name change to show in the markets this week.
PCIO will be in a better position to execute its business plan once the name change is official as excitement grows for the future of the company in the hemp and cannabis related industries.
Once the name change becomes official in the stock market, PCIO will take the next steps in the process of providing complete public disclosures required by the SEC under rule 15c211 on the OTC Markets web site.
Recently, PCIO reported the pending application for a true cannabis derived remedy. This formulation for pain management, one of the integral properties of cannabis, may help those suffering pain from a myriad of diseases.
Formulator and inventor Reverend Dr. Douglas Van Dyke stated, “This Shamanistic blend of herbs has shown great promise for pain management treatment among a closed group of patients. The probability of efficacy among a large control group is quite feasible and we welcome the opportunity to prove the formulation.”
PCIO has several other planned patent applications waiting to be filed including a topical lotion.
More about PCIO at www.Marijuana-Incorporated.com
**************************************************************
CGEN, Compugen Ltd.
CGEN is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, CGEN’s discovery efforts are based on in silico (by computer) prediction and selection utilizing a growing number of field focused proprietary discovery platforms accurately modeling biological processes at the molecular level.
** CGEN reported that it will host a live webcast and conference call at 10:00 AM EDT on Tuesday, July 27, 2010 to review second quarter 2010 results.
In addition, Dr. Anat Cohen-Dayag, CGEN’s president and CEO, will give a slide presentation illustrating the medical and commercial potential of the Company’s “discovery on demand” capabilities using CGEN’s recently announced product candidate for autoimmune disease, CGEN-15001, as an example.
The quarterly results will be released, and the slide presentation posted on CGEN’s website.
More about CGEN at www.cgen.com.
**************************************************************
ACOR, Acorda Therapeutics, Inc.
ACOR is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and other nervous system disorders.
** ACOR reported the National Heart, Lung, and Blood Institute (NHLBI) has awarded a $1 million Cardiac Translational Research Implementation Program (C-TRIP) grant to support research on Glial Growth Factor 2 (GGF2), a novel investigational agent for the treatment of patients with heart failure under development at Acorda.
The grant, supporting both clinical and laboratory studies, was awarded jointly to ACOR and Vanderbilt University Heart and Vascular Institute, which are collaborating on research of GGF2 in heart failure.
The first clinical study for GGF2 in patients with heart failure is expected to begin in mid-2010.
More about ACOR at www.acorda.com
**************************************************************
VIVO, Meridian Bioscience, Inc.
VIVO is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies.
** VIVO reported that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.
More about VIVO at www.meridianbioscience.com
**************************************************************
**************************************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations.
Tags: ACOR, Acorda Therapeutics, CGEN, Compugen, Crown Equity Holdings, CRWE, CRWE.OB, Marijuana Incorporated, Meridian Bioscience, Nasdaq: ACOR, NASDAQ: CGEN, NASDAQ: VIVO, OTC: CRWE, OTC: PCIO, OTCBB: CRWE, PCIO, pcio.pk, pinksheets: PCIO, VIVO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
